| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/50 - 1/200 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MHC; HLAC; HLC-C; D6S204; PSORS1; HLA-JY3 |
| Entrez GeneID | 3107 |
| clone | 3H3A5 |
| WB Predicted band size | 40.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human HLA-C (AA: 25-308) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于HLA-C抗体的3篇代表性文献的简要信息：
1. **文献名称**：*The clinical impact of HLA-Cw antibodies in organ transplantation*
**作者**：Kirsten M. Locke, et al.
**摘要**：该研究探讨HLA-C抗体在器官移植中的临床意义，发现HLA-Cw抗体与移植物排斥反应相关，但其致敏强度可能低于HLA-A/B抗体，需结合其他免疫因素综合评估风险。
2. **文献名称**：*HLA-C antibody-mediated endothelial cell damage in antibody-associated rejection*
**作者**：Rene J. Duquesnoy, et al.
**摘要**：通过体外实验验证HLA-C抗体对血管内皮细胞的激活作用，揭示其在抗体介导的移植排斥(AMR)中的潜在机制，强调HLA-C分型在供受体匹配中的重要性。
3. **文献名称**：*HLA-C antibodies in pre-eclampsia: a systematic review*
**作者**：Sarah L. Rogers, et al.
**摘要**：系统综述了妊娠期HLA-C抗体与子痫前期的关联，提出母体对胎儿HLA-C抗原的免疫应答可能参与胎盘血管功能障碍，但需更多临床数据支持。
*注*：若需具体文献全文或扩展领域(如HLA-C与HIV免疫逃逸等)，可进一步补充关键词或研究场景。
HLA-C antibodies are a class of human leukocyte antigen (HLA) antibodies targeting the HLA-C molecules, which belong to the HLA Class I family. HLA-C is encoded by genes within the major histocompatibility complex (MHC) on chromosome 6 and plays a critical role in immune regulation, particularly in mediating interactions between natural killer (NK) cells and antigen-presenting cells. Unlike HLA-A and HLA-B, HLA-C exhibits lower surface expression but is highly polymorphic, contributing to its significance in transplant immunology and autoimmune diseases.
These antibodies typically arise from alloimmunization events, such as blood transfusions, pregnancies, or organ transplants. In transplantation, preformed or de novo HLA-C antibodies can trigger antibody-mediated rejection (AMR) by binding to donor endothelial cells, activating complement pathways, and promoting graft injury. Their clinical impact, though historically understudied compared to HLA-A/B antibodies, is increasingly recognized, particularly in kidney and hematopoietic stem cell transplantation.
HLA-C antibodies are also implicated in pregnancy-related complications. Maternal-fetal HLA-C mismatch can induce antibody production, potentially linked to recurrent miscarriages or fetal growth restriction. Detection methods include solid-phase assays (e.g., Luminex-based single-antigen bead tests), which enhance sensitivity for identifying donor-specific antibodies. Management strategies involve desensitization protocols, immunosuppressive therapies, or careful donor selection to avoid antigenic mismatches. Ongoing research aims to clarify their pathogenicity and refine risk stratification in clinical settings.
×
